Entry

D12296                      Drug

Name

Tebentafusp (USAN/INN);
Tebentafusp-tebn;
Kimmtrak (TN)

Product

KIMMTRAK (Immunocore Commercial LLC)

Sequence

(Heavy chain)
AIQMTQSPSS LSASVGDRVT ITCRASQDIR NYLNWYQQKP GKAPKLLIYY TSRLESGVPS
RFSGSGSGTD YTLTISSLQP EDFATYYCQQ GNTLPWTFGQ GTKVEIKGGG GSGGGGSGGG
GSGGGGSGGG SEVQLVESGG GLVQPGGSLR LSCAASGYSF TGYTMNWVRQ APGKGLEWVA
LINPYKGVST YNQKFKDRFT ISVDKSKNTA YLQMNSLRAE DTAVYYCARS GYYGDSDWYF
DVWGQGTLVT VSSGGGGSDG GITQSPKYLF RKEGQNVTLS CEQNLNHDAM YWYRQDPGQG
LRLIYYSWAQ GDFQKGDIAE GYSVSREKKE SFPLTVTSAQ KNPTAFYLCA SSWGAPYEQY
FGPGTRLTVT EDLKNVFPPE VAVFEPSEAE ISHTQKATLV CLATGFYPDH VELSWWVNGK
EVHSGVCTDP QPLKEQPALN DSRYALSSRL RVSATFWQDP RNHFRCQVQF YGLSENDEWT
QDRAKPVTQI VSAEAWGRAD
(Light chain)
AQQGEEDPQA LSIQEGENAT MNCSYKTSIN NLQWYRQNSG RGLVHLILIR SNEREKHSGR
LRVTLDTSKK SSSLLITASR AADTASYFCA TDGSTPMQFG KGTRLSVIAN IQKPDPAVYQ
LRDSKSSDKS VCLFTDFDSQ TNVSQSKDSD VYITDKCVLD MRSMDFKSNS AVAWSNKSDF
ACANAFNNSI IPEDT
(Disulfide bridge: H23-H88, H153-H227, H281-H349, H401-H466, H427-L157, L23-L89, L132-L182)

Type

Peptide

Remark

Product:

D12296<US>

Efficacy

Antineoplastic

Disease

Uveal melanoma (HLA-A*02:01-positive) [DS:H00038]

Comment

Fusion protein
Treatment of uveal melanoma

Target

CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]

Pathway

hsa04660

T cell receptor signaling pathway

Brite

Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3
     D12296  Tebentafusp (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D12296
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D12296
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D12296
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D12296

Other DBs

CAS:	1874157-95-5